Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90


Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer.

Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R.

Cancer. 2009 Nov 15;115(22):5309-18. doi: 10.1002/cncr.24602.


Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.

Meng Z, Garrett CR, Shen Y, Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L.

Br J Cancer. 2012 Jul 24;107(3):411-6. doi: 10.1038/bjc.2012.283. Epub 2012 Jul 10.


Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis.

Xie X, Huang X, Li J, Lv X, Huang J, Tang S, Sun Y.

Med Hypotheses. 2013 Aug;81(2):243-50. doi: 10.1016/j.mehy.2013.04.038. Epub 2013 May 18.


A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.

Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR.

Invest New Drugs. 2000 Feb;18(1):83-91.


Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR.

Anticancer Drugs. 2013 Nov;24(10):1079-83. doi: 10.1097/CAD.0000000000000009.


Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.

Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A.

Cancer. 2012 Nov 15;118(22):5580-7. doi: 10.1002/cncr.27576. Epub 2012 Apr 27.


Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft.

Yin JH, Zhu XY, Shi WD, Liu LM.

BMC Complement Altern Med. 2014 Dec 13;14:483. doi: 10.1186/1472-6882-14-483.


Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.

Hainsworth JD, Burris HA 3rd, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA.

Cancer. 1999 Mar 15;85(6):1269-76.


Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.

Li S, Huang H, Liao H, Zhan J, Guo Y, Zou BY, Jiang WQ, Guan ZZ, Yang XQ.

Int J Clin Pharmacol Ther. 2013 Feb;51(2):96-105. doi: 10.5414/CP201761.


Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.

Chang GC, Tsai CM, Hsia TC, Yang CH, Abdulnabi R, Blair JM, Linn C.

J Formos Med Assoc. 2013 Sep;112(9):518-26. doi: 10.1016/j.jfma.2012.02.030. Epub 2013 Sep 21.


[Effect of traditional Chinese medicine treatment as maintenance therapy on regulating the serum concentration of sCTLA-4 in patients with advanced non-small-cell lung cancer and its relationship with prognosis].

Jiang Y, Wu LB, Shen LP, Zhang P, Jiang WJ, Tian JH, Liu LS.

Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):757-762. doi: 10.3760/cma.j.issn.0253-3766.2016.10.009. Chinese.


Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma.

Froudarakis ME, Pataka A, Pappas P, Anevlavis S, Argiana E, Nikolaidou M, Kouliatis G, Pozova S, Marselos M, Bouros D.

Cancer. 2008 Nov 15;113(10):2752-60. doi: 10.1002/cncr.23921.


Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.

Jia N, Liou I, Halldorson J, Carithers R, Perkins J, Reyes J, Yeh M, Stohr E, Rao S, Lin EH.

Anticancer Res. 2013 Jun;33(6):2797-800.


Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.

Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F.

Lung Cancer. 2011 Sep;73(3):338-44. doi: 10.1016/j.lungcan.2011.01.001. Epub 2011 Feb 5.


Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.

Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V.

J Thorac Oncol. 2009 Sep;4(9):1148-55. doi: 10.1097/JTO.0b013e3181ae280f.


Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.

Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-81-S12-88.


Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM.

J Clin Oncol. 2002 Sep 15;20(18):3815-25.


Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.

Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14.


A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.

Lee DH, Han JY, Yoon SM, Lee JJ, Lee HG, Kim HY, Yoon SJ, Hong EK, Lee JS.

Am J Clin Oncol. 2006 Apr;29(2):143-7.


Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.

Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB.

J Clin Oncol. 2009 Sep 1;27(25):4116-23. doi: 10.1200/JCO.2008.20.2515. Epub 2009 Jul 27.

Supplemental Content

Support Center